Skip to main navigation
Skip to search
Skip to main content
University of Birmingham Home
Help & FAQ
Home
Research output
Profiles
Research units
Projects
Activities
Datasets
Equipment
Prizes
Press/Media
Search by expertise, name or affiliation
ZIBOTENTAN Endothelin ETA Receptor Antagonist Oncolytic
Nicholas James
, JW Growcott
Cancer Research UK Clinical Trials Unit
Research output
:
Contribution to journal
›
Article
89
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'ZIBOTENTAN Endothelin ETA Receptor Antagonist Oncolytic'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Receptor Antagonist
100%
Oncolytic
100%
Endothelin Receptor
100%
Zibotentan
100%
Endothelin-1 (ET-1)
37%
ETA Receptor
37%
Receptor-mediated
25%
Phase II Trial
25%
Hormone-sensitive Prostate Cancer
25%
ETB Receptor
25%
No Significant Difference
12%
Apoptotic Pathway
12%
Clinical Development
12%
Treatment Group
12%
Adverse Events
12%
Amino Acids
12%
Metastasis
12%
Placebo
12%
Overall Survival
12%
Specific Binding
12%
Prostate Cancer
12%
Angiogenesis
12%
Anti-apoptotic
12%
Biological Effects
12%
Clinical Setting
12%
Invasiveness
12%
Headache
12%
Randomized Placebo-controlled Trial
12%
Time to Progression
12%
Nasal Congestion
12%
Tumor Xenograft
12%
Pain Patients
12%
Peripheral Edema
12%
Binding Profile
12%
Pharmacological Activities
12%
Mildly Symptomatic
12%
ZD4054
12%
Adverse Effect Profile
12%
Pharmacology, Toxicology and Pharmaceutical Science
Receptor Antagonist
100%
Endothelin
100%
Zibotentan
100%
Receptor
55%
Prostate Cancer
33%
Endothelin 1
33%
Adverse Event
22%
Placebo
22%
Neoplasm
11%
Preclinical Study
11%
Antiapoptotic
11%
Overall Survival
11%
Amino Acid
11%
Isoprenaline
11%
Phase II Trials
11%
Headache
11%
Peripheral Edema
11%
Pharmacological Activity
11%
Nose Obstruction
11%